Pt Te story IFN-γ (XMG1.2) Rat mAb (FITC Conjugate) IFN-γ (XMG1.2) Rat mAb (FITC Conjugate)



Orders:	877-616-CELL (2355) orders@cellsignal.com
Support:	877-678-TECH (8324)
Web:	info@cellsignal.com cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: FC-FP	Reactivity: M	Sensitivity: Endogenous	Source/Isotype: Rat IgG1 kappa	UniProt ID: #P01580	Entrez-Gene Id: 15978		
Product Usage		For optimal flow cytometry results, we recommend 0.125 μ g of antibody per test.					
Information		Application Flow Cytometry (Fixed/Permeabilized)			Dilution 1:400		
Storage		Supplied in 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, 0.1% gelatin, pH 7.2. This product is stable for 12 months when stored at 4°C. Do not aliquot the antibody. Protect from light. Do not freeze.					
Specificity/Sensi	tivity	IFN-γ (XMG1.2) Rat mAb (FITC Conjugate) recognizes endogenous levels of total IFN-γ protein. This antibody detects an epitope within the intracellular domain.					
Source / Purifica	ication This monoclonal antibody was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation.						
Description		This Cell Signaling Technology antibody is conjugated to FITC and tested in-house for direct flow cytometric analysis in mouse cells.					
Background		IFN-γ plays key roles in both the innate and adaptive immune response. IFN-γ activates the cytotoxic activity of innate immune cells, such as macrophages and NK cells (1,2). IFN-γ production by NK cells and antigen presenting cells (APCs) promotes cell-mediated adaptive immunity by inducing IFN-γ production by T lymphocytes, increasing class I and class II MHC expression, and enhancing peptide antigen presentation (1). Due to differences in the degree of glycosylation, there are three forms of IFN-γ, with approximate molecular weights of 25, 20, and 15.5 kDa by SDS-PAGE (5). The anti-viral activity of IFN-γ is due to its induction of PKR and other regulatory proteins. Binding of IFN-γ to the IFNGR1/IFNGR2 complex promotes dimerization of the receptor complexes to form the (IFNGR1/IFNGR2) ₂ -IFN-γ dimer. Binding induces a conformational change in receptor intracellular domains and signaling involves Jak1, Jak2, and Stat1 (3). The critical role of IFN-γ in amplification of immune surveillance and function is supported by increased susceptibility to pathogen infection by IFN-γ or IFNGR knockout mice and in humans with inactivating mutations in <i>IFNGR1</i> or <i>IFNGR2</i> . IFN-γ also appears to have a role in atherosclerosis (4).					
Background Ref	erences	1. Schroder, K. et al. (2004) <i>J Leukoc Biol</i> 75, 163-89. 2. Martinez, F.O. et al. (2009) <i>Annu Rev Immunol</i> 27, 451-83. 3. Kotenko, S.V. et al. (1995) <i>J Biol Chem</i> 270, 20915-21. 4. McLaren, J.E. and Ramji, D.P. (2009) <i>Cytokine Growth Factor Rev</i> 20, 125-35. 5. Kelker, H.C. et al. (1984) <i>J Biol Chem</i> 259, 4301-4.					
Species Reactivit	v	Species reactivity is deterr	mined by testing in at lea	ast one approved app	olication (e.g., western blot).		
Applications Key	-	FC-FP: Flow Cytometry (Fixed/Permeabilized)					
Cross-Reactivity	Кеу	M: Mouse					
Trademarks and	Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.					
		All other trademarks are t more information.	he property of their resp	ective owners. Visit	cellsignal.com/trademarks for		
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no					

force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.